($ billions, except per-
share amounts) Fourth Quarter Full Year
2005 2004 2005 2004
Revenue $13.592 $14.924 $51.298 $52.516
Reported Net Income $2.732 $2.825 $8.085 $11.361
Reported Diluted EPS $0.37 $0.38 $1.09 $1.49
Adjusted Income(1) $3.765 $4.385 $15.001 $16.136
Adjusted Diluted
EPS(1) $0.51 $0.58 $2.02 $2.12
[see end of text prior to tables]
- - -
Stronger Than Expected Results Driven by In-Line Medicines, Performance of New
Medicines, and Accelerated Cost Savings
- - -
Lipitor Revenue Up 12 Percent Worldwide in 2005;
Lyrica One of Most Successful Pfizer Launches Ever;
Worldwide Geodon Revenue Up 26 Percent; Pipeline Advances,
With Six Promising Medicines In U.S. Regulatory Review, Including Sutent and
Champix, Which Have Been Granted Priority Review
- - -
'Adapting to Scale' Cost Savings of $800 Million,
Double 2005 Goal
- - -
Quarter Includes Important Lipitor Patent Victories
and 26-Percent Dividend Increase
- - -
Pfizer Continues To Invest in Future Growth;
Reaches Agreement to Acquire Worldwide Rights to Exubera,
Innovative Diabetes Product Candidate
- - -
Factors Driving Performance in 2006 May Differ from 2005;
Company Analyst Meeting Is February 10
NEW YORK, Jan. 19 /PRNewswire-FirstCall/ -- Pfizer reported fourth-quarter
and full-year 2005 financial results today that reflect operating and
financial strength, with performance exceeding expectations, driven by in-line
medicines, new medicines, and accelerated cost savings, all while promising
candidates continue to advance through the company's pipeline.
"We are supporting our key in-line and newly launched medicines, driving
important new medicines through the pipeline and taking a series of specific
actions to build Pfizer's value," said Hank McKinnell, chairman and chief
executive officer. "We completed the year with positive news on many fronts
-- including double-digit full-year worldwide growth of Lipitor; an
exceptional Lyrica launch in the U.S.; priority-review status for two
potential breakthrough medicines, Sutent for cancer and Champix for smoking
cessation; favorable decisions in Lipitor patent cases; and a 26-percent
dividend increase for the first quarter of 2006. Our strategy of driving
growth in our in-line medicines and investing in promising new medicines is
the essence of the new Pfizer. We will continue to focus on enhancing value
for our shareholders and meeting patients' needs worldwide."
Dr. McKinnell said there were two primary drivers for Pfizer's better-
than-expected performance in the quarter: better revenue performance in the
Human Health business; and operating expense savings, coupled with the
acceleration of the "Adapting to Scale" (AtS) cost savings to $800 million in
2005, which is double the goal for the year.
"While we are pleased that Pfizer's performance in 2005 exceeded previous
expectations, investors should be aware that the factors driving Pfizer's
performance may differ materially in 2006," Dr. McKinnell added. "We look
forward to providing a full briefing on our 2006 financial guidance, strategy,
products, and pipeline at our analyst meeting in New York on February 10. We
enter the new year with renewed determination to capitalize on all the
opportunities we see to bring our innovative medicines to those who need
them."
Portfolio, Pipeline Position Human Health for Future Success
"2005 has been a challenging year for Pfizer Human Health," said Karen
Katen, vice chairman of Pfizer Inc and president of Pfizer Human Health.
"However, fourth-quarter and full-year 2005 results indicate that we are
well-positioned for the future, with a solid in-line portfolio and a rich
pipeline of innovative new medicines."
Loss of exclusivity in the U.S. of certain key medicines, uncertainty
related to Celebrex, and the suspension of Bextra sales cumulatively reduced
2005 worldwide revenue by $5.7 billion. As a result, total Pfizer Human
Health revenue declined $1.8 billion, or 4 percent, for full-year 2005
compared to full-year 2004. In the U.S., Human Health revenue declined 12
percent for the full-year 2005 compared to the same period in 2004.
Excluding the major medicines that lost exclusivity in the U.S. in 2004
and 2005 and the selective COX-2 inhibitors, Human Health adjusted revenues(2)
grew 11 percent worldwide and 10 percent in the U.S. for full-year 2005
compared to 2004. The successful launches of seven new medicines over the
past two years are enabling Pfizer to replenish our portfolio. The combined
sales of these products (Inspra, Caduet, Olmetec, Macugen, Revatio, Zmax, and
Lyrica) generated $284 million in fourth-quarter 2005 revenue and $632 million
in full-year 2005 revenue worldwide.
Many of Pfizer's top medicines achieved double-digit growth worldwide in
2005 compared to 2004 across many therapeutic areas, including
cardiovascular/metabolic diseases (Lipitor up 12 percent, Caduet up 272
percent); central nervous system disorders (Geodon up 26 percent, Relpax up 38
percent); infectious and respiratory diseases (Zyvox up 33 percent, Vfend up
38 percent); oncology (Aromasin up 73 percent); and ophthalmology
(Xalatan/Xalacom up 12 percent).
Fourth-Quarter Portfolio Highlights
The cardiovascular portfolio continues to perform well. Cardiovascular
sales include another billion-dollar quarter for Norvasc and continued
momentum for Caduet, which achieved 323-percent revenue growth worldwide in
the fourth quarter to $65 million. Worldwide sales of Lipitor totaled $3.4
billion in the fourth quarter, reflecting growth of 3 percent over the
previous year's quarter, a difficult comparison in light of Lipitor's 23-
percent revenue growth in the fourth quarter of 2004, exacerbated by four
fewer business days in the 2005 quarter. Full-year sales of $12.2 billion
reflected 12-percent growth over 2004.
In the recently published IDEAL study, Lipitor was shown to be numerically
superior to Zocor in the secondary prevention of cardiovascular events. This
difference fell just short of statistical significance (p=0.07 vs.
significance at p=0.05). Lipitor did achieve statistically significant
improvements in major secondary endpoints, including a 13-percent reduction in
major cardiovascular events and a 17-percent reduction in non-fatal heart
attacks for patients taking Lipitor 80 mg compared to patients taking
simvastatin (Zocor) 20 and 40 mg. These results affirm that intensive lipid-
lowering with Lipitor 80 mg can safely provide benefits beyond the most
commonly prescribed doses of Zocor (20 and 40 mg) in patients with coronary
artery disease.
The performance of the central nervous system portfolio was fueled by the
launch of Lyrica. Since its September launch, more than 500,000 prescriptions
have been written for Lyrica in the U.S. as of December 23, 2005. Lyrica had
already gained more than a 7-percent new-prescription share of the U.S. anti-
epileptic market as of December 23, continuing its performance as one of
Pfizer's most successful pharmaceutical launches. This mirrors the
outstanding launch performance seen globally. On a worldwide basis, Geodon
exhibited strong full-year growth of 26 percent. This performance far
outpaced the rate of market growth. In the U.S., Geodon is the second-
fastest-growing atypical anti-psychotic oral medication in new-prescription
volume as of November year-to-date. Its balance of powerful efficacy and a
favorable metabolic profile positions it for further growth.
In the ophthalmology portfolio, the 9-percent worldwide growth in audited
sales of Xalatan/Xalacom outpaced market growth (IMS MIDAS data for the twelve
months ending November 2005). These medicines continue to lead the worldwide
glaucoma market with a 35.7-percent share of revenues during the same period.
Pfizer recently launched the first fully validated glaucoma risk calculator,
which will help physicians identify patients with ocular hypertension who are
most likely to progress to glaucoma, and determine whether to initiate earlier
therapy. Macugen has become an important treatment in the U.S. for wet age-
related macular degeneration, the leading cause of blindness in people over
60. While new competitors are expected to enter the market, Macugen has a
strong foothold with more than 40,000 patients treated to date. Macugen's
favorable safety profile has been maintained for more than two years of
clinical testing and marketing.
Despite decreased usage in prescription pain medications, Celebrex
continues to be a leader in this field with a 46-percent share of U.S. anti-
inflammatory sales and a 22-percent share worldwide for November 2005. In the
fourth quarter of 2005, Celebrex was the fastest-growing medicine in the U.S.
anti-inflammatory market. Pfizer is currently supporting the Cleveland
Clinic's 20,000-patient prospective study to definitively evaluate the
relative safety of Celebrex and two older pain medications in patients with
heart disease or at high risk of heart disease.
Worldwide full-year 2005 Viagra sales declined 2 percent. Fourth-quarter
2005 sales declined 8 percent, versus the comparable period in 2004,
reflecting slower growth in the overall erectile-dysfunction (ED) market and
competition from other products. Viagra continues to lead the ED market and
is capturing six out of ten new prescriptions for ED in the U.S. through
November 2005 year-to-date. Pfizer is supporting consumer ED education with
the recent launch of a new unbranded educational campaign in the U.S.
Rich Pipeline of New Medicines Continues to Advance
"We continue to make excellent progress toward our goal of filing 20 major
new medicines in the U.S. in the five-year period ending in 2006," said Dr.
John LaMattina, President of Pfizer Global Research and Development.
In addition to the seven products launched in 2004 and 2005, six
additional products are under review by the FDA. Priority review has been
granted for three of these -- Sutent (sunitinib), Champix (varenicline), and
Eraxis (anidulafungin).
* Sutent is an oral agent with anti-angiogenic and anti-tumor activity
that may offer significant advantage to physicians treating patients
with metastatic renal cell carcinoma and Gleevec-resistant
gastrointestinal stromal tumors.
* Champix, a novel partial nicotinic agonist for smoking cessation, has
been shown to be more effective than the only other oral anti-smoking
prescription medicine.
* In a recent study, the antifungal agent Eraxis has shown significant
benefit over fluconazole in the treatment of candidemia and invasive
candidiasis and has received an approvable letter from the FDA for
esophageal candidiasis.
Three other products are currently under review by the FDA:
* Exubera, the inhaled insulin drug for type 1 and type 2 diabetes,
represents the first non-injectable form of insulin available for
diabetics. It has been recommended for approval by the FDA advisory
committee and for marketing authorization by the Committee for Medicinal
Products in Europe. Pfizer has reached an agreement to acquire sanofi-
aventis's share of worldwide rights to Exubera, as well as the insulin
production facilities located in Frankfurt previously jointly owned by
the two companies.
* Indiplon is filed for two NDAs for the treatment of adult insomnia, in
immediate-release and modified-release formulations.
* We have received an approvable letter from the FDA for Zeven
(dalbavancin), a once-weekly intravenous antibiotic for the treatment
of complicated skin and skin-structure infections caused by Gram-
positive bacteria, including methicillin-resistant Staphylococcus
aureus. This is Pfizer's second major product filing resulting from the
recent acquisition of Vicuron.
"And we reached several important milestones during the fourth quarter in
our ongoing efforts to bring new innovative therapies to patients around the
world," said Dr. LaMattina.
Ticilimumab (CP-675,206), an anti-CTLA4 receptor antagonist, began Phase 3
testing in December. The compound is a monoclonal antibody and another
addition in Pfizer's growing pipeline of large-molecule biologics.
Ticilimumab may offer an important new option for treating metastatic
melanoma, which has a five-year survival rate of less than 10 percent.
In 2005, Pfizer extended our long history of successful alliances and
acquisitions with a series of agreements with Angiosyn, BioRen, Coley, Idun,
Incyte, Renovis, Rigel, and Vicuron, several of which are already
demonstrating strong results. In the fourth quarter of 2005, Pfizer began two
Phase 3 trials for non-small-cell lung cancer using a novel anti-cancer agent
PF-3512676 (formerly CpG 7909), licensed from Coley Pharmaceutical Group.
Based on Phase 2 survival data, this compound may offer a significant
advancement over current therapies in treating non-small-cell lung cancer.
Pfizer also entered a global collaborative research and licensing
agreement with Incyte Corporation in the fourth quarter of 2005, giving us
exclusive worldwide development and commercialization rights to a portfolio of
CCR2 antagonist compounds for the potential treatment of inflammation. The
most advanced compound is currently in Phase 2a studies in rheumatoid
arthritis and insulin-resistant obese patients.
Leveraging Financial Strength
"Pfizer is undertaking a series of actions to employ the company's strong
positive cash flow for the short- and long-term benefit of shareholders," said
David Shedlarz, vice chairman. "Given the strength of our operations, in
December 2005 we increased our dividend for the first quarter of 2006 by 26
percent to 24 cents per share, while continuing to invest for long-term
growth. With this increase, Pfizer will have increased dividends every year
for 39 consecutive years. In 2005, we repatriated nearly $37 billion in
foreign earnings, which Pfizer is using to enhance its balance sheet and
invest in business opportunities. In addition, the company purchased nearly
$4 billion in common stock in 2005, and it will continue to buy back its stock
in 2006. Pfizer's sterling triple-A credit rating was also reaffirmed by
Standard & Poor's and Moody's.
"With these and other actions, we are demonstrating to shareholders our
commitment to work to enhance the value of their investment in Pfizer," Mr.
Shedlarz concluded.
"Pfizer's earnings performance in the fourth quarter reflected operational
flexibility, exceeding the estimate we announced in October 2005 for a number
of reasons," said Alan Levin, senior vice president and chief financial
officer. "Human Health revenues were stronger than previously forecast,
reflecting an unexpected two-week delay in the introduction of azithromycin
(Zithromax) generics in the U.S., strong early market acceptance of Lyrica,
and better-than-anticipated performance in certain key markets (Japan and
Germany) and in certain key products (Zyrtec and Norvasc). The fourth quarter
of 2005 had four fewer business days than the fourth quarter of 2004; this is
reflected in more tempered revenues and operating expenditures for the
quarter. Full-year 2005 figures reflect a comparable number of days to 2004.
"Cost of sales for the quarter remained under pressure, although the
impact of changes in the geographic, product, and segment mix of our products
was partially mitigated by the favorable impact of foreign exchange during the
quarter. The modest rate of growth in Selling, Informational and
administrative expenses and the decline in Research and Development
expenditures is due in part to greater savings associated with our Adapting to
Scale (AtS) initiative. For the full year, AtS savings of approximately $800
million were realized, double our original goal for the year. We also
achieved approximately $4.2 billion in synergies through 2005 in connection
with our acquisition and integration of Pharmacia Corporation.
"Relative to prior expectations, fourth-quarter and full-year reported net
income and diluted EPS reflect our enhanced operating performance during the
quarter, partially offset by higher AtS implementation costs," Mr. Levin
concluded.
Pfizer Continues Aggressive Defense of Intellectual Property
With Important Lipitor, Norvasc Victories
In December 2005, Pfizer prevailed in a U.S. court decision involving a
patent challenge to Lipitor, the world's most popular cholesterol-lowering
medicine. The U.S. District Court for the District of Delaware determined
that two U.S. patents covering atorvastatin, the active ingredient in Lipitor,
are valid and infringed by the product of generic manufacturer Ranbaxy Labs
LTD (Ranbaxy), thus protecting Lipitor's exclusivity until June 2011.
The U.S. decision marked one more major victory over Ranbaxy, which is
using legal challenges in an attempt to overturn Pfizer's atorvastatin patents
in the U.S. and many other markets. In October 2005, the United Kingdom's
High Court upheld the exclusivity of the basic patent covering atorvastatin.
The ruling prohibits Ranbaxy from introducing a generic version of
atorvastatin in the U.K. until the patent expires in November 2011. Both the
U.S. and U.K. decisions have been appealed.
"Lipitor represents nothing less than one of the most important medical
breakthroughs from pharmaceutical research, and the courts are sending a clear
message that the legal system should support and encourage this kind of
innovation," said Jeffrey Kindler, vice chairman and general counsel. "We
continue to believe that policymakers should examine a system in which generic
companies can take as many 'shots on goal' as they wish, employing lawyers,
not medical researchers, around the world to undermine confidence in research-
based companies and the jobs they support. Our only course is to aggressively
defend our patents and stand for principles we believe in, on behalf of the
patients we serve and the future of medical innovation."
In a separate case, Pfizer announced yesterday that the U.S. District
Court for the Northern District of Illinois upheld Pfizer's U.S. patent
covering amlodipine besylate, the active ingredient in Norvasc, which had been
challenged by the generic manufacturer Apotex.
Disaster Relief Efforts, Access Initiatives
Highlight Corporate Citizenship
Pfizer continues to make progress in its initiatives to expand access to
medicines and healthcare resources and to demonstrate excellence in corporate
citizenship.
During 2005, the company made substantial contributions to the relief and
recovery efforts in response to an unprecedented series of natural disasters,
including the Asian tsunami, Hurricanes Katrina and Rita in the U.S. Gulf
States, and the earthquake that struck Pakistan and India. In partnership
with relief organizations and local authorities in the affected regions,
Pfizer and its colleagues donated funds, medicines, and healthcare supplies
and supported the rebuilding of critical healthcare infrastructure.
The company also advanced healthcare programs and partnerships in the
developing world during 2005, including a program to train medical
professionals across Africa in diagnosis and management of patients with HIV,
malaria, and tuberculosis; a multi-country initiative to eliminate trachoma,
the world's leading cause of preventable blindness; and a program in 42
developing countries to train healthcare providers in the treatment of
opportunistic infections associated with HIV/AIDS.
Pfizer Changing to Meet Changing Times
"While 2005 was one of the most difficult years in memory, it ended well,"
Dr. McKinnell concluded. "2005 will be seen as a pivotal year in Pfizer's
history -- the last year of the old Pfizer. We are once again doing what
every generation of Pfizer colleagues has had to do since the late 1800s --
change our company to meet changing times."
For additional details, please see the attached financial schedules,
product revenue tables, supplemental financial information, and Disclosure
Notice.
(1) "Adjusted income" and "adjusted diluted earnings per share (EPS)"
are defined as reported net income and reported diluted EPS,
excluding discontinued operations, cumulative effect of a change in
accounting principles, purchase accounting adjustments, merger-
related costs, and certain significant items. As described under
Adjusted Income in the Management's Discussion and Analysis of
Financial Condition and Results of Operations section of Pfizer's
Form 10-Q for the quarterly period ended October 2, 2005, management
uses adjusted income, among other factors, to set performance goals
and to measure the performance of the overall company. We believe
that investors' understanding of our performance is enhanced by
disclosing this measure. A reconciliation to reported net income and
reported diluted EPS is provided in the table accompanying this
report. The adjusted income and adjusted diluted EPS measures are
not, and should not be viewed as, substitutes for U.S. GAAP net
income and diluted EPS.
(2) Human Health adjusted revenues are defined as total Human Health
revenues excluding the revenues of selective COX-2 inhibitors and
major products that have lost exclusivity in the U.S. since the
beginning of 2004. See the table accompanying this report.
PFIZER INC AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
(millions of dollars, except per common share data)
Fourth Quarter %Incr./ Full Year %Incr./
2005 2004 (Decr.) 2005 2004 (Decr.)
Revenues $13,592 $14,924 (9) $51,298 $52,516 (2)
Costs and expenses:
Cost of sales 2,346 2,356 - 8,525 7,541 13
Selling,
informational and
administrative
expenses 4,755 4,676 2 16,997 16,903 1
Research and
development
expenses 2,020 2,328 (13) 7,442 7,684 (3)
Amortization of
intangible assets 833 868 (4) 3,409 3,364 1
Merger-related in-
process research
and development
charges - 116 * 1,652 1,071 54
Restructuring
charges and merger-
related costs 596 467 28 1,392 1,193 17
Other
(income)/deductions
--net (323) 614 * 347 753 (54)
Income from
continuing
operations before
provision for taxes
on income, minority
interests and
cumulative effect
of a change
in accounting
principles 3,365 3,499 (4) 11,534 14,007 (18)
Provision for taxes
on income 610 625 (2) 3,424 2,665 28
Minority interests 7 3 121 16 10 59
Income from
continuing
operations before
cumulative effect of
a change
in accounting
principles 2,748 2,871 (4) 8,094 11,332 (29)
Discontinued
operations:
Income/(loss) from
discontinued
operations--net of
tax 6 (49) * (31) (22) 42
Gains on sales of
discontinued
operations--net of
tax 3 3 - 47 51 (8)
Discontinued
operations--net of
tax 9 (46) * 16 29 (45)
Income before
cumulative effect of
a change in
accounting
principles 2,757 2,825 (2) 8,110 11,361 (29)
Cumulative effect of
a change in
accounting
principles--net of
tax (25) - * (25) - *
Net income $2,732 $2,825 (3) $8,085 $11,361 (29)
Earnings per common
share - Basic:
Income from
continuing
operations before
cumulative
effect of a
change in
accounting
principles $0.37 $0.39 (5) $1.10 $1.51 (27)
Discontinued
operations --
net of tax - (0.01) * - - *
Income before
cumulative effect
of a change in
accounting
principles 0.37 0.38 (3) 1.10 1.51 (27)
Cumulative effect of
a change in
accounting
principles --
net of tax - - * - - *
Net income $0.37 $0.38 (3) $1.10 $1.51 (27)
Earnings per common
share - Diluted:
Income from
continuing
operations before
cumulative
effect of a
change in
accounting
principles $0.37 $0.39 (5) $1.09 $1.49 (27)
Discontinued
operations --
net of tax - (0.01) * - - *
Income before
cumulative effect
of a change in
accounting
principles 0.37 0.38 (3) 1.09 1.49 (27)
Cumulative effect of
a change in
accounting
principles--net of
tax - - * - - *
Net income $0.37 $0.38 (3) $1.09 $1.49 (27)
Weighted-average
shares used to
calculate earnings
per common share:
Basic 7,327 7,461 7,361 7,531
Diluted 7,368 7,511 7,411 7,614
* Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.
(1) The above financial statement presents the three-month and twelve-
month periods ended December 31 of each year. Subsidiaries operating
outside the United States are included for the three-month and twelve-
month periods ended November 30 of each year.
(2) As required, the estimated value of Merger-related in-process research
and development charges (IPR&D) is expensed at acquisition date. In
2005, we expensed $1.7 billion of IPR&D, of which $1.4 billion related
to our acquisition of Vicuron Pharmaceuticals, Inc. in the third
quarter and $250 million related to our acquisition of Idun
Pharmaceuticals, Inc. in the second quarter. In 2004, we expensed
$1.1 billion of IPR&D, of which $920 million related to our
acquisition of Esperion Therapeutics, Inc. in the first quarter.
(3) Other (income)/deductions -- net in the fourth quarter of 2004
includes a charge of $691 million in connection with an intangible
asset impairment related to Depo-Provera. Other (income)/deductions --
net in 2005 includes an impairment charge of $1.2 billion related to
the developed technology rights and the write-off of machinery and
equipment for Bextra, a selective COX-2 inhibitor. Other
(income)/deductions -- net in 2004 includes a charge of $691 million
in connection with an intangible asset impairment related to
Depo-Provera and $369 million in connection with certain litigation-
related charges.
(4) Provision for taxes on income in 2005 includes tax benefits associated
with the resolution of certain tax positions ($586 million) and taxes
on the repatriation of foreign earnings ($1.7 billion).
(5) In December 2005, we adopted the provisions of the Financial
Accounting Standards Board (FASB) Interpretation No. 47, Accounting
for Conditional Asset Retirement Obligations (FIN 47), a new
accounting interpretation issued in March 2005. As a result, we
recorded a non-cash pre-tax charge of $40 million ($25 million, net of
tax) for costs associated with the eventual retirement of certain
facilities. This charge is reported as a one-time cumulative effect of
a change in accounting principle in the fourth quarter of 2005.
PFIZER INC AND SUBSIDIARY COMPANIES
RECONCILIATION FROM REPORTED NET INCOME AND REPORTED DILUTED EARNINGS PER
SHARE TO ADJUSTED INCOME AND ADJUSTED DILUTED EARNINGS PER SHARE
(UNAUDITED)
(millions of dollars, except per common share data)
Fourth Quarter %Incr./ Full Year %Incr./
2005 2004 (Decr.) 2005 2004 (Decr.)
Reported net income $2,732 $2,825 (3) $8,085 $11,361 (29)
Purchase accounting
adjustments -- net of
tax 572 831 (31) 3,973 3,389 17
Merger-related costs --
net of tax 227 323 (30) 624 786 (21)
Discontinued operations
-- net of tax (9) 46 * (16) (29) (45)
Cumulative effect of a
change in accounting
principles -- net of
tax 25 - * 25 - *
Certain significant
items -- net of tax 218 360 (39) 2,310 629 268
Adjusted income $3,765 $4,385 (14) $15,001 $16,136 (7)
Reported diluted
earnings per common
share $0.37 $0.38 (3) $1.09 $1.49 (27)
Purchase accounting
adjustments -- net of
tax 0.08 0.10 (20) 0.54 0.45 20
Merger-related costs --
net of tax 0.03 0.04 (25) 0.08 0.10 (20)
Discontinued operations
-- net of tax - 0.01 * - - *
Cumulative effect of a
change in accounting
principles -- net of
tax - - * - - *
Certain significant
items -- net of tax 0.03 0.05 (40) 0.31 0.08 288
Adjusted diluted
earnings per common
share $0.51 $0.58 (12) $2.02 $2.12 (5)
* Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.
(1) The above reconciliation presents the three-month and twelve-month
periods ended December 31 of each year. Subsidiaries operating outside
the United States are included for the three-month and twelve-month
periods ended November 30 of each year.
(2) Adjusted Income and Adjusted diluted earnings per common share as
shown above reflect the following items:
(millions of dollars) Fourth Quarter Full Year
2005 2004 2005 2004
Purchase accounting adjustments,
pre-tax:
In-process research and
development charges (a) $- $116 $1,652 $1,071
Intangible amortization and
other (b) 805 835 3,295 3,285
Sale of acquired inventory
written up to fair value (c) - 40 4 40
Total purchase accounting
adjustments, pre-tax 805 991 4,951 4,396
Income taxes (233) (160) (978) (1,007)
Total purchase accounting
adjustments -- net of tax 572 831 3,973 3,389
Merger-related costs, pre-tax:
Integration costs (d) 160 129 550 496
Restructuring costs (d) 161 338 393 697
Total merger-related costs,
pre-tax 321 467 943 1,193
Income taxes (94) (144) (319) (407)
Total merger-related costs --
net of tax 227 323 624 786
Discontinued operations, pre-tax:
(Gain)/loss from discontinued
operations (e) (11) 81 33 39
Gains on sales of discontinued
operations (e) (5) (7) (77) (75)
Total discontinued operations,
pre-tax (16) 74 (44) (36)
Income taxes 7 (28) 28 7
Total discontinued operations --
net of tax (9) 46 (16) (29)
Cumulative effect of change in
accounting principles -- net of tax 25 - 25 -
Certain significant items, pre-tax
Asset impairment charges and
other costs associated with the
suspension of selling Bextra (f) 16 - 1,232 -
Litigation charge (g) - - - 369
Impairment of Depo-Provera
intangible asset (g) - 691 - 691
Other legacy Pharmacia intangible
asset impairment (g) - 11 - 11
Contingent income earned from
2003 sale of product-in-
development (g) - (100) - (100)
Operating results of divested
legacy Pharmacia research
facility (h) - - - 64
Restructuring charges - Adapting
to Scale (d) 276 - 450 -
Implementation costs - Adapting
to Scale (i) 194 - 330 -
Gain on disposals of investments (g) (134) - (134) -
Asset impairment charges related
to Elleste (g) 8 - 8 -
Total certain significant items,
pre-tax 360 602 1,886 1,035
Income taxes (106) (242) (654) (406)
Resolution of certain tax
positions (j) - - (586) -
Tax impact for the repatriation
of foreign earnings (j) (36) - 1,664 -
Total certain significant
items -- net of tax 218 360 2,310 629
Total purchase accounting
adjustments, merger-
related costs, discontinued
operations, cumulative effect of
change in accounting principles
and certain significant items --
net of tax $1,033 $1,560 $6,916 $4,775
(a) Included in Merger-related in-process research and development
charges.
(b) Included primarily in Amortization of intangible assets.
(c) Included in Cost of sales.
(d) Included in Restructuring charges and merger-related costs.
(e) Included in Discontinued operations -- net of tax.
(f) Included in Cost of sales ($17 million), partially offset by Other
(income)/deductions-net (($1) million) for the three months ended
December 31, 2005, and included in Cost of sales ($73 million),
Selling, informational and administrative expenses ($8 million) and
Other (income)/deductions-net ($1.2 billion) for the twelve months
ended December 31, 2005.
(g) Included in Other (income)/deductions-net.
(h) Included in Research and development expenses.
(i) Included in Cost of sales ($87 million), Selling, informational and
administrative expenses ($75 million), and Research and development
expenses ($32 million) for the three months ended December 31, 2005,
and included in Cost of sales ($124 million), Selling, informational
and administrative expenses ($156 million), and Research and
development expenses ($50 million) for the twelve months ended
December 31, 2005.
(j) Included in Provision for taxes on income.
PFIZER INC AND SUBSIDIARY COMPANIES
RECONCILIATION FROM HUMAN HEALTH REPORTED REVENUES
TO HUMAN HEALTH ADJUSTED REVENUES
(UNAUDITED)
(millions of dollars)
Worldwide
Fourth Quarter %Incr./ Full Year %Incr./
2005 2004 (Decr.) 2005 2004 (Decr.)
Total Human Health
revenues $11,655 $13,101 (11) $44,284 $46,133 (4)
Celebrex 472 1,008 (53) 1,730 3,302 (48)
Bextra (2) 417 * (61) 1,286 *
Dynastat 8 14 (44) 34 46 (25)
Accupril/Accuretic 44 165 (74) 294 665 (56)
Neurontin 141 481 (71) 639 2,723 (77)
Zithromax 382 672 (43) 2,000 1,842 9
Diflucan 128 139 (8) 498 945 (47)
Human Health adjusted
revenues $10,482 $10,205 3 $39,150 $35,324 11
U.S.
Fourth Quarter %Incr./ Full Year %Incr./
2005 2004 (Decr.) 2005 2004 (Decr.)
Total Human Health
revenues $6,240 $7,616 (18) $23,443 $26,583 (12)
Celebrex 357 719 (50) 1,267 2,363 (46)
Bextra (2) 346 * (82) 1,116 *
Dynastat - - - - - -
Accupril/Accuretic (25) 90 * 22 387 (94)
Neurontin 27 352 (92) 159 2,198 (93)
Zithromax 249 545 (54) 1,484 1,393 7
Diflucan (1) 1 * (17) 417 *
Human Health adjusted
revenues $5,635 $5,563 1 $20,610 $18,709 10
International
Fourth Quarter %Incr./ Full Year %Incr./
2005 2004 (Decr.) 2005 2004 (Decr.)
Total Human Health
revenues $5,415 $5,485 (1) $20,841 $19,550 7
Celebrex 115 289 (60) 463 939 (51)
Bextra - 71 * 21 170 *
Dynastat 8 14 (44) 34 46 (25)
Accupril/Accuretic 69 75 (8) 272 278 (2)
Neurontin 114 129 (11) 480 525 (9)
Zithromax 133 127 5 516 449 15
Diflucan 129 138 (6) 515 528 (2)
Human Health adjusted
revenues $4,847 $4,642 4 $18,540 $16,615 12
* Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.
(1) Human Health adjusted revenues, which excludes the revenues of
selective COX-2 inhibitors and major products which have lost
exclusivity in the U.S. since the beginning of 2004, is an alternative
view of our Human Health revenue performance and we believe that
investors' understanding of Human Health revenue growth is enhanced by
disclosing this performance measure. Zithromax, Neurontin, Diflucan
and Accupril/Accuretic recently lost their U.S. exclusivity and, as is
typical in the pharmaceutical industry, this has resulted in a
dramatic decline in revenues due to generic competition. Celebrex and
Bextra, as a result of a recent regulatory evaluation of the risks and
benefits of all COX-2 medicines, have also experienced a significant
decline in sales. Specifically, the regulatory review of and
conclusions regarding Celebrex have resulted in a reduction in sales
this year as physicians evaluate the evolving information on the risks
and benefits of all NSAIDs and revised labeling, and on April 7, 2005,
the FDA requested the suspension of Bextra sales and marketing based
on its assessment of an unfavorable risk/benefit profile due to the
additional increased risk of rare, serious skin reactions compared to
other NSAIDs. We believe that excluding the impact of these products
assists the reader in understanding the underlying strength of the
balance of our diverse Human Health product portfolio in 2005.
Because of its non-standardized definition, this adjusted Human Health
revenues measure has limitations as it may not be comparable with the
calculation of similar measures of other companies. This additional
revenue measure is not, and should not be viewed as, a substitute for
the U.S. GAAP comparison of Human Health revenue growth.
PFIZER INC
SEGMENT/PRODUCT REVENUES
FOURTH QUARTER 2005
(UNAUDITED)
(millions of dollars)
WORLDWIDE U.S. INTERNATIONAL
% % %
2005 2004 Chg 2005 2004 Chg 2005 2004 Chg
TOTAL
REVENUES 13,592 14,924 (9) 7,106 8,417 (16) 6,486 6,507 -
HUMAN
HEALTH 11,655 13,101 (11) 6,240 7,616 (18) 5,415 5,485 (1)
- CARDIOVASCULAR
AND
METABOLIC
DISEASES 5,068 5,077 - 2,787 2,810 (1) 2,281 2,267 1
LIPITOR 3,357 3,264 3 2,069 2,023 2 1,288 1,241 4
NORVASC 1,244 1,253 (1) 613 619 (1) 631 634 (1)
CARDURA 146 168 (13) 2 1 107 144 167 (14)
CADUET 65 15 323 63 15 317 2 - *
ACCUPRIL/
ACCURETIC 44 165 (74) (25) 90 * 69 75 (8)
- CENTRAL
NERVOUS
SYSTEM
DISORDERS 1,673 2,020 (17) 1,023 1,364 (25) 650 656 (1)
ZOLOFT 808 959 (16) 653 768 (15) 155 191 (19)
GEODON/
ZELDOX 159 143 11 131 118 11 28 25 11
LYRICA 153 11 M+ 82 - * 71 11 567
NEURONTIN 141 481 (71) 27 352 (92) 114 129 (11)
XANAX/XR 102 106 (3) 35 37 (5) 67 69 (2)
ARICEPT ** 90 87 4 - - - 90 87 4
RELPAX 63 54 16 38 33 14 25 21 20
- ARTHRITIS
AND PAIN 647 1,607 (60) 402 1,108 (64) 245 499 (51)
CELEBREX 472 1,008 (53) 357 719 (50) 115 289 (60)
BEXTRA (2) 417 * (2) 346 * - 71 *
- INFECTIOUS
AND
RESPIRATORY
DISEASES 1,110 1,339 (17) 513 776 (34) 597 563 6
ZITHROMAX/
ZMAX 402 675 (40) 262 545 (52) 140 130 7
ZYVOX 164 135 21 118 99 19 46 36 27
DIFLUCAN 128 139 (8) (1) 1 * 129 138 (6)
VFEND 112 83 34 40 33 19 72 50 45
- UROLOGY 727 769 (5) 410 461 (11) 317 308 3
VIAGRA 430 469 (8) 212 248 (15) 218 221 (1)
DETROL/
DETROL LA 283 285 (1) 193 207 (7) 90 78 15
- ONCOLOGY 497 453 10 167 182 (8) 330 271 22
CAMPTOSAR 237 189 25 124 123 1 113 66 69
ELLENCE 94 90 5 17 18 (4) 77 72 7
AROMASIN 71 49 44 25 17 44 46 32 44
- OPHTHALMOLOGY 362 353 2 116 123 (5) 246 230 7
XALATAN/
XALACOM 361 353 2 116 123 (5) 245 230 7
- ENDOCRINE
DISORDERS 266 257 4 86 84 3 180 173 4
GENOTROPIN 204 200 2 60 57 7 144 143 -
- ALL OTHER 997 981 2 553 554 (1) 444 427 5
ZYRTEC/
ZYRTEC D 327 349 (6) 327 349 (6) - - -
- ALLIANCE
REVENUE
(Aricept,
Macugen,
Mirapex,
Olmetec,
Rebif
and
Spiriva) 308 245 26 183 154 19 125 91 37
CONSUMER
HEALTHCARE 1,043 992 5 503 490 3 540 502 7
ANIMAL
HEALTH 630 566 11 283 231 22 347 335 4
OTHER *** 264 265 - 80 80 - 184 185 -
* - Calculation not meaningful.
** - Represents direct sales under license agreement with Eisai Co., Ltd.
*** - Includes Capsugel and Pfizer CenterSource.
M+ - Change greater than one-thousand percent.
Certain amounts and percentages may reflect rounding adjustments.
Certain 2004 data have been reclassified to conform to the 2005
presentation.
PFIZER INC
SEGMENT/PRODUCT REVENUES
TWELVE MONTHS 2005
(UNAUDITED)
(millions of dollars)
WORLDWIDE U.S. INTERNATIONAL
% % %
2005 2004 Chg 2005 2004 Chg 2005 2004 Chg
TOTAL
REVENUES 51,298 52,516 (2) 26,664 29,539 (10) 24,634 22,977 7
HUMAN
HEALTH 44,284 46,133 (4) 23,443 26,583 (12) 20,841 19,550 7
- CARDIOVASCULAR
AND
METABOLIC
DISEASES 18,732 17,412 8 10,036 9,256 8 8,696 8,156 7
LIPITOR 12,187 10,862 12 7,401 6,634 12 4,786 4,228 13
NORVASC 4,706 4,463 5 2,222 1,991 12 2,484 2,472 -
CARDURA 586 628 (7) 7 6 6 579 622 (7)
ACCUPRIL/
ACCURETIC 294 665 (56) 22 387 (94) 272 278 (2)
CADUET 185 50 272 179 49 265 6 1 766
- CENTRAL
NERVOUS
SYSTEM
DISORDERS 6,391 8,092 (21) 3,816 5,668 (33) 2,575 2,424 6
ZOLOFT 3,256 3,361 (3) 2,573 2,657 (3) 683 704 (3)
NEURONTIN 639 2,723 (77) 159 2,198 (93) 480 525 (9)
GEODON/
ZELDOX 589 467 26 483 385 26 106 82 29
XANAX/XR 409 378 8 141 123 14 268 255 5
ARICEPT ** 346 308 12 - - - 346 308 12
LYRICA 291 13 M+ 111 - * 180 13 M+
RELPAX 233 169 38 143 100 43 90 69 31
- ARTHRITIS
AND PAIN 2,376 5,203 (54) 1,377 3,608 (62) 999 1,595 (37)
CELEBREX 1,730 3,302 (48) 1,267 2,363 (46) 463 939 (51)
BEXTRA (61) 1,286 * (82) 1,116 * 21 170 *
- INFECTIOUS
AND
RESPIRATORY
DISEASES 4,766 4,715 1 2,450 2,664 (8) 2,316 2,051 13
ZITHROMAX/
ZMAX 2,025 1,851 9 1,497 1,393 7 528 458 15
ZYVOX 618 463 33 438 339 29 180 124 44
DIFLUCAN 498 945 (47) (17) 417 * 515 528 (2)
VFEND 397 287 38 140 118 18 257 169 53
- UROLOGY 2,684 2,634 2 1,497 1,539 (3) 1,187 1,095 9
VIAGRA 1,645 1,678 (2) 802 886 (10) 843 792 7
DETROL/
DETROL LA 988 904 9 675 633 7 313 271 15
- ONCOLOGY 1,996 1,502 33 701 629 12 1,295 873 48
CAMPTOSAR 910 554 64 471 449 5 439 105 317
ELLENCE 367 344 7 73 66 11 294 278 6
AROMASIN 247 143 73 85 41 109 162 102 58
- OPHTHALMOLOGY 1,373 1,227 12 432 419 3 941 808 16
XALATAN/
XALACOM 1,372 1,227 12 432 419 3 940 808 16
- ENDOCRINE
DISORDERS 1,049 925 13 341 298 14 708 627 13
GENOTROPIN 808 736 10 239 208 15 569 528 8
- ALL OTHER 3,852 3,702 4 2,176 2,090 4 1,676 1,612 4
ZYRTEC/
ZYRTEC D 1,362 1,287 6 1,362 1,287 6 - - -
- ALLIANCE
REVENUE
(Aricept,
Macugen,
Mirapex,
Olmetec,
Rebif
and
Spiriva) 1,065 721 48 617 412 50 448 309 45
CONSUMER
HEALTHCARE 3,878 3,516 10 1,941 1,780 9 1,937 1,736 12
ANIMAL
HEALTH 2,206 1,953 13 993 878 13 1,213 1,075 13
OTHER *** 930 914 2 287 298 (4) 643 616 4
* - Calculation not meaningful.
** - Represents direct sales under license agreement with Eisai Co., Ltd.
*** - Includes Capsugel and Pfizer CenterSource.
M+ - Change greater than one-thousand percent.
Certain amounts and percentages may reflect rounding adjustments.
Certain 2004 data have been reclassified to conform to the 2005
presentation.
PFIZER INC
SUPPLEMENTAL FINANCIAL INFORMATION
1) Impact of Foreign Exchange on Revenues
Changes in foreign-exchange rates in the fourth quarter of 2005 relative
to the same period in the prior year had a nominally favorable impact on
revenue growth of $36 million, or 0.2%. The weakness of the U.S. dollar
relative to other currencies, primarily the euro, Canadian dollar, Brazilian
real, and British pound, for the twelve months of 2005 compared to the twelve
months of 2004 favorably impacted full-year 2005 revenues by $945 million, or
1.8%.
2) Impact of Accounting Calendar on Revenues
Pfizer's accounting calendar had three additional business days in the
first quarter relative to 2004. Pfizer's second and third fiscal quarters of
2005 had the same number of business days as the prior year. The fourth
quarter, however, had four fewer business days than the prior year (six fewer
calendar days).
3) Change in Cost of Sales
Cost of sales as a percentage of revenues increased to 17.3% in the fourth
quarter of 2005 from 15.8% in the fourth quarter of 2004. The increase in the
cost of sales margin principally reflects unfavorable geographic, segment, and
product mix; adverse changes in production volume; and AtS costs ($87
million); partially offset by a favorable impact of foreign exchange.
Cost of sales as a percentage of revenues increased to 16.6% for the
twelve months of 2005 from 14.4% for the twelve months of 2004. The increase
reflects unfavorable geographic, segment, and product mix; adverse changes in
production volume; AtS costs ($124 million); and costs associated with Bextra
($73 million), among other factors.
4) Costs Relating to Adapting to Scale Productivity Initiative
Costs relating to the Adapting to Scale (AtS) initiative were $470 million
and $780 million, pre-tax, for the three months and twelve months ended
December 31, 2005. We expect the costs associated with this multi-year effort
to continue through 2008 and to total $4 billion to $5 billion, on a pre-tax
basis. The actions associated with the AtS initiative will include
restructuring charges -- such as asset impairments, exit costs, and severance
and severance-related costs -- and associated implementation costs, such as
accelerated depreciation charges, primarily associated with plant network
optimization efforts, and expenses associated with system and process
standardization and the expansion of shared services.
5) Merger-Related Costs
Pharmacia merger-related costs totaled $928 million for 2005. Cumulative
costs from 2002 through 2005 were $5.4 billion, consistent with expectations
at the time of the acquisition. Merger-related synergies through 2005 totaled
approximately $4.2 billion. Pharmacia merger-related initiatives are
essentially complete, and we will not incur material Pharmacia merger-related
costs going forward.
6) Other Income and Other Deductions
($ millions) Fourth Quarter Full Year
2005 2004* 2005 2004*
Net Interest (Income)
/Expense $(110) $(2) $ (269) $1
Various Litigation Matters 2 3 2 369
Impairment of Bextra
-Related Long-Lived
Assets (2) - 1,150 -
Impairment of Depo-Provera
Intangible Assets - 691 - 691
Other Intangible Asset
Impairments 8 11 8 11
Royalties (102) (50) (369) (288)
Contingent Income Earned
from 2003 Sale of Product
in Development - (100) - (100)
Gains on Disposals of
Investments/Product Lines (118) (10) (188) (16)
Other, Net (1) 71 13 85
Other (Income)/Deductions
-Net $(323) $614 $347 $753
* Certain 2004 amounts were reclassified to conform to the 2005
presentation.
In connection with the decision to suspend sales of Bextra in the first
quarter of 2005, we recorded a charge of $1.1 billion relating to the
impairment of Bextra's intangible assets for developed technology rights and
the write-off of machinery and equipment of $5 million.
In the third quarter of 2004, Pfizer recorded a litigation-related charge
of $369 million related to the resolution of claims against Quigley Company,
Inc., a wholly owned subsidiary of Pfizer.
In the fourth quarter of 2004, we recorded a non-cash charge of $691
million upon determining that an indefinite-lived intangible asset relating to
Depo-Provera had become impaired.
7) Effective Tax Rate
The effective tax rate used in calculating reported income for 2005 is
29.7%. The effective tax rate used in calculating adjusted income(1) is
22.2%. The difference between the adjusted tax rate and the reported tax rate
primarily reflects the tax impact on foreign earnings repatriated pursuant to
the American Jobs Creation Act, resolution of certain tax positions, as well
as the tax impacts of purchase accounting and the Bextra impairment.
8) Share-Purchase Program
We believe that purchase of our stock is an excellent investment
opportunity. Since the beginning of 1999, Pfizer has purchased more than
$35.6 billion of its common stock. In the second quarter of 2005, the company
completed the $5 billion share-purchase program authorized in October 2004.
On June 23, 2005, Pfizer announced the authorization of a new $5 billion
share-purchase program. By the end of 2005, Pfizer had purchased
approximately 22 million shares valued at approximately $493 million under the
new program. In total, the company purchased nearly 144 million shares of
common stock, valued at $3.8 billion, during 2005. We remain committed to
completing our new $5 billion share-purchase program.
DISCLOSURE NOTICE: The information contained in this document and the
attachments is as of January 19, 2006. The Company assumes no obligation to
update any forward-looking statements contained in this document or the
attachments as a result of new information or future events or developments.
This document and the attachments contain forward-looking information
about the Company's financial results and estimates, business prospects, in-
line products and products in research that involve substantial risks and
uncertainties. You can identify these statements by the fact that they use
words such as "will," "anticipate," "estimate," "expect," "project," "intend,"
"plan," "believe," "target," "forecast", and other words and terms of similar
meaning in connection with any discussion of future operating or financial
performance. Among the factors that could cause actual results to differ
materially are the following:
* the success of research and development activities;
* decisions by regulatory authorities regarding whether and when to
approve our drug applications as well as their decisions regarding
labeling and other matters that could affect the commercial potential of
our products;
* the speed with which regulatory authorizations, pricing approvals and
product launches may be achieved;
* competitive developments affecting our current growth products;
* the ability to successfully market both new and existing products
domestically and internationally;
* difficulties or delays in manufacturing;
* trade buying patterns;
* the ability to meet generic and branded competition after the loss of
patent protection for our products or for competitor products;
* the impact of existing and future regulatory provisions on product
exclusivity;
* trends toward managed care and health care cost containment;
* possible U.S. legislation or regulatory action affecting, among other
things, pharmaceutical pricing and reimbursement, including under
Medicaid and Medicare, the importation of prescription drugs that are
marketed outside the U.S. and sold at prices that are regulated by
governments of various foreign countries, and the involuntary approval
of prescription medicines for over-the-counter use;
* the potential impact of the Medicare Prescription Drug, Improvement and
Modernization Act of 2003;
* legislation or regulations in markets outside the U.S. affecting product
pricing, reimbursement or access;
* contingencies related to actual or alleged environmental contamination;
* claims and concerns that may arise regarding the safety or efficacy of
in-line products and product candidates;
* legal defense costs, insurance expenses, settlement costs and the risk
of an adverse decision or settlement related to product liability,
patent protection, governmental investigations, ongoing efforts to
explore various means for resolving asbestos litigation and other legal
proceedings;
* the Company's ability to protect its patents and other intellectual
property both domestically and internationally;
* interest rate and foreign currency exchange rate fluctuations;
* governmental laws and regulations affecting domestic and foreign
operations, including tax obligations;
* changes in generally accepted accounting principles;
* any changes in business, political and economic conditions due to the
threat of future terrorist activity in the U.S. and other parts of the
world, and related U.S. military action overseas;
* growth in costs and expenses;
* changes in our product mix; and
* the impact of acquisitions, divestitures, restructurings, product
withdrawals, and other unusual items, including our ability to integrate
and to obtain the anticipated results and synergies from our acquisition
of Pharmacia, and our ability to realize the projected benefits of our
Adapting to Scale multi-year productivity initiative.
A further list and description of these risks, uncertainties and other
matters can be found in the Company's Annual Report on Form 10-K for the
fiscal year ended December 31, 2004, and in its reports on Forms 10-Q and 8-K.
This document includes discussion of certain clinical studies relating to
various in-line products and/or product candidates. These studies typically
are part of a larger body of clinical data relating to such products or
product candidates, and the discussion herein should be considered in the
context of the larger body of data.
SOURCE Pfizer Inc
 back to top
Related links:
http://www.pfizer.com
Company News On-Call:
http://www.prnewswire.com/comp/688250.html
Photo Notes:A free corporate logo to accompany this
story is available immediately via Wieck Photo Database to any
media with telephoto receiver or electronic darkroom, PC or
Macintosh, that can accept overhead transmissions. To retrieve a
logo, please call 972-392-0888
Company News On-Call: Pfizer's press releases are
available through PR Newswire's Company News On-Call service on
PRN's Web Site. Visit
http://www.prnewswire.com/comp/688250.html
CONTACT:
Andy McCormick, +1-212-733-5469, or Paul
Fitzhenry, +1-212-733-4637, both of Pfizer Inc
|
